Drug intelligence / Profile preview

cladosporium sphaerospermum

Development stage: Preclinical
Lead developer: ALK Abelló
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Subcutaneous, Intradermal, Percutaneous

Overview

Cladosporium sphaerospermum is a species of fungus that is being investigated as a potential live biotherapeutic product for the treatment of Crohn's disease. Research suggests that it is depleted in the gut mucosa of patients with Crohn's disease, and that its presence can counteract intestinal inflammation. [10] This therapeutic effect is believed to be mediated in part by its production of adenosine 5'-monophosphate (AMP). [10] It has also been shown to strengthen the gut barrier by upregulating epithelial cell junctions and the Wnt signaling pathway. [10] Outside of its potential therapeutic use, C. sphaerospermum is a ubiquitous, darkly-pigmented mold found in various environments. [5] It is studied in many other contexts, including as a plant pathogen, a rare human pathogen, a biocontrol agent for agriculture, a source of novel bioactive compounds like enzymes and potential antivirals, and for its ability to degrade plastics and tolerate high levels of radiation. [8, 14]

Targets

ENTPD1 (Ectonucleoside triphosphate diphosphohydrolase 1)

Beyond the preview

Go deeper on cladosporium sphaerospermum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cladosporium sphaerospermum.

Explore the full profile